Feng Jun, Fang Bangjiang, Zhou Daixing, Wang Junshuai, Zou Dengxiu, Yu Gang, Fen Yikuan, Peng Dan, Hu Jifa, Zhan Daqian
Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China.
Department of Emergency Medicine, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China.
J Microbiol Biotechnol. 2021 Mar 28;31(3):380-386. doi: 10.4014/jmb.2009.09029.
The coronavirus disease 2019 (COVID-19) pandemic has become a public health emergency of global concern. In China, traditional Chinese medicine has been widely administered to COVID-19 patients without sufficient evidence. To evaluate the efficacy of Shenhuang Granule (SHG) for treating critically ill patients with COVID-19, we included in this study 118 patients who were admitted to the ICU of Tongji Hospital between January 28, 2020 and March 28, 2020. Among these patients, 33 (27.9%) received standard care plus SHG (treatment group) and 85 (72.1%) received standard care alone (control group). Enrolled patients had a median (IQR) age of 68 (57-75) years, and most (79 [67.1%]) were men. At end point of this study, 83 (70.3%) had died in ICU, 29 (24.5%) had been discharged from ICU, and 6 patients (5.2%) were still in ICU. Compared with control group, mortality was significantly lower in treatment group (45.4% vs. 80%, < .001). Patients in treatment group were less likely to develop acute respiratory distress syndrome (ARDS) (12 [36.3%] vs. 54 [63.5%], = 0.012) and cardiac injury (5 [15.1%] vs. 32 [37.6%], = 0.026), and less likely to receive mechanical ventilation (22 [66.7%] vs. 72 [84.7%], = 0.028) than those in control group. The median time from ICU admission to discharge was shorter in treatment group (32 [20-73] days vs. 76 [63-79] days, = 0.0074). These findings suggest that SHG treatment as a complementary therapy might be effective for critically ill adults with COVID-19 and warrant further clinical trials.
2019年冠状病毒病（COVID-19）大流行已成为全球关注的突发公共卫生事件。在中国，在没有充分证据的情况下，中药已被广泛应用于COVID-19患者。为了评估神黄颗粒（SHG）治疗COVID-19重症患者的疗效，我们纳入了本研究中2020年1月28日至2020年3月28日期间入住同济医院重症监护病房的118例患者。在这些患者中，33例（27.9%）接受标准治疗加SHG（治疗组），85例（72.1%）仅接受标准治疗（对照组）。入组患者的年龄中位数（IQR）为68（57-75）岁，大多数（79例[67.1%]）为男性。在本研究的终点，83例（70.3%）在重症监护病房死亡，29例（24.5%）从重症监护病房出院，6例患者（5.2%）仍在重症监护病房。与对照组相比，治疗组的死亡率显著降低（45.4%对80%，<0.001）。治疗组患者发生急性呼吸窘迫综合征（ARDS）的可能性较小（12例[36.3%]对54例[63.5%]，=0.012）和心脏损伤的可能性较小（5例[15.1%]对32例[37.6%]，=0.026），并且接受机械通气的可能性比对照组小（22例[66.7%]对72例[84.7%]，=0.028）。治疗组从入住重症监护病房到出院的中位时间较短（32[20-73]天对76[63-79]天，=0.0074）。这些发现表明，SHG治疗作为一种辅助疗法可能对COVID-19重症成人患者有效，值得进一步进行临床试验。
